secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-04-15T23:59:59+00:00
Accession:  0001140361-22-014768
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics reports FY2021 net loss of $122.3M; cash $17M
-------------------------------------------------------------------------

- Net loss $122.3M for FY2021 vs $26.5M in 2020; Q4 loss $8.5M vs $21.5M.
- Operating expenses $113.6M, including $80.5M acquired IPR&D from Novellus deal.
- Cash $17.0M at Dec 31, 2021, up from $1.6M a year ago; raised $52M via equity sales.
- Completed Novellus acquisition in July 2021; new executives appointed.
- Phase 2b head & neck cancer trial readout for IRX-2 expected Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122014768/0001140361-22-014768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122014768/brhc10036443_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-014768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer